-81%

est. 2Y upside i

HealthcareSeries A

Pacagen is house of brands focused on disrupting consumer industries through biotechnology-backed products built by our in-house research lab. We are actively incubating new technologies in the immune, inflammation, and consumer health spaces.

Rank

#3842

Sector

Biotechnology

Est. Liquidity

~6Y

Data Quality

Data: Medium

Pacagen is an early-stage biotechnology company with a proprietary approach to allergen management, but it presents a risky equity opportunity.

Last updated: March 10, 2026

Bull (10%)+300%

Pacagen successfully validates its efficacy claims with robust, peer-reviewed clinical data, overcoming TINA.org's concerns. It expands its product line beyond sprays and supplements to new allergens or delivery methods, securing significant market share in the $3.5B SAM. Strategic partnerships with major consumer health companies drive revenue to $50M+ by 2028, justifying a $260M valuation.

Base (35%)+50%

Pacagen achieves moderate growth, reaching $5-10M in revenue by 2028. It carves out a niche against direct competitors like Allerpet but faces ongoing pressure and market education challenges from larger incumbents like Purina and the emerging threat of Regeneron's internal therapies, leading to a modest valuation of $97.5M.

Bear (55%)-80%

TINA.org's concerns about efficacy lead to increased regulatory scrutiny and consumer distrust, hindering market adoption. Regeneron's advanced internal antibody therapies gain significant traction, marginalizing Pacagen's external solutions. This results in a down round or a low-value acquisition at $13M, severely impacting common stock value.

Est. time to liquidity~6.0 years

Preference Stack Risk

high

Investors hold $13M in liquidation preferences, representing 20% of the assumed $65M current valuation.

Dilution Risk

high

As an early-stage company, Pacagen will likely require additional funding rounds, leading to further dilution for common stock holders.

Secondary Liquidity

none

Given its early stage and private status, there is currently no active secondary market for Pacagen's equity.

Questions to Ask at the Interview

Strategic questions based on Pacagen's data — designed to show you've done your homework.

  • 1

    “Given Regeneron's progress with internal antibody therapies for cat allergies, how does Pacagen plan to differentiate and maintain its competitive edge in the long term, especially considering the different mechanisms of action of your products versus their systemic treatments?”

  • 2

    “With TINA.org raising questions about the 98% efficacy claims and lack of peer-reviewed data, what is Pacagen's strategy to generate and publish robust scientific evidence to build consumer and regulatory trust?”

  • 3

    “Considering the current ~$1M run-rate and $13M in Series A funding, what are the key milestones for the next 18-24 months that would justify a significant step-up in valuation for a potential Series B round, and how does the company plan to achieve them?”

Community

Valuation Sentiment

Our model estimates -81% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.